During a live event, Mark J. Fesler, MD, and participants discussed selection and timing of initiation of JAK inhibitor therapy for myelofibrosis.
JAK Inhibitor Therapy in the Myeloproliferative Neoplasm Population
During a live event, Mark J. Fesler, MD, and participants discuss next steps for a 68-year-old patient with intermediate-risk myelofibrosis.
During a live event, Andrew Kuykendall, MD, discussed management of anemia before and during use of JAK inhibitor for myelofibrosis in the second of 2 articles.
During a Case-Based Roundtable® event, Andrew Kuykendall, MD, and participants discussed the the importance of early intervention and consideration of anemia with JAK inhibitor therapy for patients with myelofibrosis in the first article of a 2-part series.
During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the triggers physicians need to consider when deciding to initiate therapy for patients with myelofibrosis in the first article of a 2-part series.
During a Targeted Oncology™ Case-Based Roundtable™ event, Raajit K. Rampal, MD, gave an overview of the classification, risk assessment, and current therapy options for patients with myelofibrosis.
In the second article of a 2-part series, Pankit Vachhani, MD, highlights the impact ruxolitinib has had, and continues, to have in treatment for patients with myelofibrosis and how physicians should manage this treatment for their patients.
In the first article of a 2-part series, Pankit Vachhani, MD, discusses what makes classical cases of myeloproliferative neoplasms unique and how ruxolitinib impacts their reduction of spleen volume.
During a Targeted Oncology™ Case-Based Roundtable™ event, Rami Komrokji, MD, discussed elements to diagnosing myelofibrosis and how to approach risk stratification before treatment.
In the second part of a live discussion on treating patients with myelofibrosis, Jonathan Abbas, MD, led a talk on the impact of ruxolitinib for these patients and where physicians stand with the use of fedratinib.
During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed with his fellow clinicians the use of allogeneic hematopoietic stem cell transplant in patients with myeloproliferative neoplasms and how ruxolitinib fits into their care.
During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed data supporting the use of ruxolitinib and what role it may play in improving long-term outcomes for patients with myelofibrosis. This is the second of 2 articles based on this event.
During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, and participants discussed when to start treatment for patients with myelofibrosis.
During a Targeted Oncology case-based roundtable event, Pankit Vachhani, MD, discussed with participants how to assess risk and begin treatment for myelofibrosis. This is the second of 2 articles based on this event.
During a Targeted Oncology case-based roundtable event, Pankit Vachhani, MD, discussed with participants how they would diagnose a patient who potentially has primary myelofibrosis.
During a live virtual event, Ruben Mesa, MD, discussed the clinical trials and challenges of using ruxolitinib for patients with myelofibrosis.
During a live virtual event, Ruben Mesa, MD, discussed the use and sequencing of JAK inhibitors and stem cell transplant for patients with myelofibrosis.